DC-FEELM
29.9.2022 14:46:40 CEST | Business Wire | Press release
FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, has won the Golden Leaf Award for "Most Promising Innovation" at the 2022 Global Tobacco and Nicotine Forum (GTNF) in Washington, DC.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005491/en/
GTNF event site (Photo: Business Wire)
“Using FEELM’s updated ceramic coil technology, the FEELM Max offers improved flavor consistency, more puffs and reduced harshness through smaller aerosol particles. Most importantly, the FEELM Max offers greater potential for harm reduction,” the organizer of GTNF announced at the award ceremony.
Four years ago, FEELM tech won the Golden Leaf Award. And four years later, FEELM Max won the Golden Leaf Award again, it is also FEELM Max's second global award this year after winning the Red Dot Award.
The Golden Leaf Award is one of the most prestigious awards in the sector and is designed to recognize companies and brands that have made outstanding contributions to the global tobacco and nicotine industry. The "Most Promising Innovation" award was open to companies that are launching new technologies and products, and was judged based on design innovation and projected future production efficiencies.
Speaking at the award ceremony, Chief Scientist of SMOORE American Research Institute, Dr. Shi, said:
"We have a long and extensive portfolio of breakthrough technologies to enhance the product experience, and we are delighted that FEELM Max has won, and our efforts have been recognized by global industry experts."
Today's new award represents another milestone in the continuing evolution of FEELM technology. With new materials, microstructures and processes, the FEELM Max technology sets a new bar in even more harm reduction and product performance improvement. It embodies the mission of the parent company Smoore International: innovation for better well-being, which ties well with the theme of this conference "Science, technology and innovation driving transformation."
According to the evaluation of industry experts, the technology within FEELM Max has the potential to bring the quality associated with reusable vaping products into the disposable market. As the world's first disposable atomization solution with a ceramic core, FEELM Max relies on its underlying technological innovation to surpass the traditional cotton core solution. It provides disposable products with "better taste, more puff, and higher consistency."
FEELM's single-use solutions are now sold in countries around the world, including in major economies like the United States, United Kingdom. SMOORE's interim financial report for 2022 showed that the revenue of disposable products in the first half of the year reached 319 million yuan, up 234.5 percent from the same period last year.
In addition to redefining products with technological innovation and creating a better vaping experience, FEELM Max also aims to have a lower carbon footprint than comparable products by introducing a series of green and sustainable technical solutions covering packaging, materials, and production.
The 2020 and 2021 GTNF awards had been postponed to 2022 due to the COVID-19 pandemic, which meant the competition was more intense than ever. The winners represented the innovations in the industry over the past three years, making FEELM even more proud to have won this award.
ENDS
For more information or journalist queries, please contact Tommy Gilchrist on 0044 7388 110 679 or via feelm@smooretech.com.
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005491/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
